CS8 TIMI 73a is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~152 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia.
MAIN RESULTS:
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
NEJM, 2024 May 16;390(19):1770-1780.
Bridge CS8 – TIMI 73a on ClinicalTrials.gov
CONTACT US about Bridge CS8 – TIMI 73a
PRESENTATIONS